Chicago, IL / AccessWire / November 21, 2022 / Cosmos Holdings d/b/a universe health, inc. (“company”) (Nasdaq: COSM), Nutraceuticals and Pharmaceuticals, a global healthcare conglomerate with distributor of branded generic, OTC drugs and medical devices, today announced that its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of airline company Iberia. British Airways Group. Ronda is available free of charge to more than 10 million passengers flying with Iberian Airlines annually.
Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircraft and operates over 600 daily flights. The magazine is in digital format via on-board screens with an interactive QR code to order on the intranet on all Iberia flights. In addition, the magazine is sent to Iberia Plus, Platinum and Gold level members, as well as Executives Plus and Frequent Flyer Premium members. Ronda’s readership has strong purchasing power, with 81% being over the age of 35 and 72% holding a higher education degree. Sky Premium Life is a proprietary, luxury and high-quality nutritional supplement brand featuring a complete line of vitamins, minerals, herbs and unique formulas.
“We are excited to sell our Sky Premium Life products on Ronda, the in-flight magazine of Iberian Airlines.” said Greg Siokas, CEO of Cosmos Health. “Ronda’s upscale and well-educated reader base is the perfect customer pool for our Sky Premium Life products. We are continuing our global roll-out strategy as we launch our products across the globe. So far we have successfully introduced our products in 2022. Amazon in the United States, the United Kingdom, Canada and Singapore, and have signed agreements to enter Germany and Austria. Our major objective is to grow internationally as we continue to leverage our strong global logistics and distribution capabilities while expanding our customer base around the world.
According to Mordor Intelligence, the European nutraceutical market is expected to grow at a CAGR of 7.5% to exceed $100 billion by 2027. The expansion of the market in Europe is attributed to the ever-increasing healthcare cost and aging population.
Cosmos Health, Inc. about
Cosmos Health Inc. (Nasdaq: COSM) is a global healthcare conglomerate incorporated in 2009 and headquartered in Chicago, Illinois. Cosmos Health operates in the nutraceutical sector through its own products “Sky Premium Life” and “Mediterranean”. Additionally, the company operates in the pharmaceutical sector through the provision of a wide range of branded generic and OTC medicines and in the healthcare distribution sector through its subsidiaries serving retail pharmacies and wholesale distributors in Greece and the UK. is included. Cosmos Health is strategically focused on the research and development of innovative patented nutraceuticals (IP) and specialty root extracts, as well as proprietary complex generic and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding across Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.
With the exception of historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. , as amended. the statements before, after, or whether he or she otherwise “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar Contains expressions or future or conditional verbs such as “will,” “should,” “shall,” “might” and “might”, are generally forward-looking in nature and are not historical facts , although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that could affect the matters discussed herein individually or materially, for a number of reasons that are beyond the control of the Company, including, but not limited to, its the Company’s ability to raise sufficient financing to implement the business plan, the impact of the COVID-19 pandemic and the war in Ukraine on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies ability. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Litham Partners, LLC
I: [email protected]
Source: Cosmos Holdings, Inc.